A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, open-label, parallel, positive-controlled
registered clinical study,to evaluate the efficacy and safety of insulin degludec injection
developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.